Opinion|Videos|August 12, 2024
The Inflation Reduction Act: Implications for Patient Access in CL
A group of experts discuss implications for patient access in CLL.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What efforts are being made to improve affordability and access to BTK inhibitors for all patients who could benefit from them?
- Ibrutinib was selected for the first round of Medicare drug price negotiations, a key component of the Inflation Reduction Act (IRA). How might this negotiation impact patient access to BTK inhibitor therapy?
Advertisement
Related to this article
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
4
Who Recommends COVID-19 Vaccines Without ACIP?
5